| Accession Number: | 0001209191-20-003457 |
| Date: | 2020-01-13 |
| Issuer: | VERTEX PHARMACEUTICALS INC / MA (VRTX) |
| Original Submission Date: |
PARINI MICHAEL
C/O VERTEX PHARMACEUTICALS INCORPORATED
50 NORTHERN AVENUE
BOSTON, MA 02210
| Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
|---|---|---|---|---|---|---|---|---|---|
| COMMON STOCK | 2020-01-13 | M | 2,125 | a | $90.29 | 37,128 | direct | ||
| COMMON STOCK | 2020-01-13 | S | 300 | d | $225.27 | 36,828 | direct | ||
| COMMON STOCK | 2020-01-13 | S | 1,225 | d | $226.42 | 35,603 | direct | ||
| COMMON STOCK | 2020-01-13 | S | 300 | d | $227.56 | 35,303 | direct | ||
| COMMON STOCK | 2020-01-13 | S | 300 | d | $228.99 | 35,003 | direct |
| Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| STOCK OPTION (RIGHT TO BUY) | 90.29 | 2020-01-13 | deemed execution date | M | 2,125 (d) | 2026-07-11 | common stock 2,125 | $90.29 | 4,250 | direct |
| ID | footnote |
|---|---|
| f1 | transaction made pursuant to mr. parini's company-approved trading plan under rule 10b5-1. |
| f2 | open market sales reported on this line occurred at a weighted average price of $225.27 (range $224.75 to $225.57). |
| f3 | mr. parini undertakes to provide (upon request by the sec staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. |
| f4 | open market sales reported on this line occurred at a weighted average price of $226.42 (range $226.06 to $227.01). |
| f5 | open market sales reported on this line occurred at a weighted average price of $227.56 (range $227.53 to $227.62). |
| f6 | open market sales reported on this line occurred at a weighted average price of $228.99 (range $228.79 to $229.27). |
| f7 | the option vests in 16 quarterly installments from 07/12/2016. |
